HeartWare International — Shareholder Meeting (October 2008)
32 slides from HeartWare International's shareholder meeting presentation, Oct 21, 2008
Slide 1: Letter to ASX Manager of Company Announcements
Manager of Company Announcements ASX Limited Level 6 20 Bridge Street SYDNEY NSW 2000 22 October 2008 BY E-LODGEMENT Dear Sir / Madam Redomiciliation Meetings In accordance with ASX Listing Rule 3.13.3 the Company provides a copy of the presentation materials that are to be delivered today at the me
Slide 2: HeartWare Limited: Leading a small revolution
HeartWare Limited (ASX:HTW) Leading a small revolution CEO Presentation Mr Doug Godshall 22 October 2008 www.heartware.com
Slide 3: Disclosures
Disclosures Not an Offer for Securities This Presentation does not constitute nor does it contain an offer or invitation to buy or subscribe for securities in HeartWare Limited (the Company) or an inducement to make an offer or invitation with respect to those securities. Forward looking Statements
Slide 4: Agenda
Agenda Redomiciliation Corporate Update US & International Clinical Trial Update Operations Update Future Products Update Milestones
Slide 5: Redomiciliation - Overview
Redomiciliation - Overview The HeartWare Group will redomicile - or reincorporate - in the United States of America HeartWare International, Inc (a US-based Delaware corporation) will become the ultimate parent company of the HeartWare Group HeartWare International will replace HeartWare Limited as
Slide 6: Redomiciliation - Continued
Redomiciliation - Continued Shareholders have the same economic interest in HeartWare before and after the transaction Shareholders will receive: 1 HeartWare International CDI per Ordinary Share held; OR 1 HeartWare International Common Stock for every 35 Ordinary Shares held CDI's and Common Stock
Slide 7: ‘ramary shares (3108) camman stack (2990) —————» ets 109)"
‘ramary shares (3108) camman stack (2990) —————» ets 109)" oy sage ry =a spf urn in oman eo =o ep ea saan er) cosas Boel cess eA enn (eC cs pea wor Eee oo cea « ocEI a pensions on mabe Eee Seer = SES, == EP o C2) A at cen of te 20 cee 208 © Asana oreotars eve Ge: at hi a conn aha bn rrr So arc en eS
Slide 8: Summary - Redomiciliation
Summary - Redomiciliation Redomiciliation will reduce costs, complications and the overall burden associated with being a dual public company "in the United States and Australia" HeartWare will become a US public company that is listed on the ASX Paves the way for a primary listing on NASDAQ The Boa
Slide 9: Physical Characteristics
Physical Characteristics Centrifugal pump 50 cc 140 grams 2 inch outside diameter Integrated inflow cannula 10 mm outflow graft with articulating strain relief Thin, flexible driveline Custom sewing ring Caution - Investigational Device, Limited by United States Law to Investigational Use
Slide 10: Implanted in Pericardial Space
Implanted in Pericardial Space Integrated inflow cannula and novel sewing ring designed to expedite the implant procedure Caution - Investigational Device, Limited by United States Law to Investigational Use
Slide 11: Implanted in Pericardial Space
Implanted in Pericardial Space Caution - Investigational Device, Limited by United States Law to Investigational Use "...you simply let the heart go and both the heart and the pump disappear into the chest..."
Slide 12: Patient and Hospital Equipment
Patient and Hospital Equipment Intuitive touch screen monitor 2 line LCD display, power connections, & log files 2 battery packs last approximately 10 hours Caution - Investigational Device, Limited by United States Law to Investigational Use
Slide 13: HeartWare LVAD physician quote
This pump offers something that no other pump offers. It has the potential to make an important difference for our patients and on the market. O. H. (Bud) Frazier M.D.; at HeartWare investigators' meeting 10-16-08 HeartWare LVAD
Slide 14: US clinical trial underway
US clinical trial underway Granted full IDE approval from FDA in September 2008 150 patients at a maximum 28 centers First US implant at Washington Hospital Centre 6 additional centers trained 2 others have received IRB Strong interest from leading transplant centres FDA Classification as a Category
Slide 15: International Clinical Trial Update
International Clinical Trial Update as of October 10, 2008 Enrolled 45 Alive on pump or transplanted 40 Transplanted 12 Recovered 3 Deceased 5* Longest in Use 22 months Total LVAD Support 30.6 pt/yrs *1 patient died on POD 203 after reaching primary endpoint Adverse events/complications consistent w
Slide 16: Kaplan-Meier: Interim Report (N = 45)
90% 86% Kaplan-Meier: Interim Report (N = 45) Caution - Investigational Device, Limited by United States Law to Investigational Use
Slide 17: International Trial Survival vs. Heart Transplantation
Months HeartWare N=40 Transplants N= 9,125 0 100 100 1 97 93.284 2 94 91.552 3 90 90.597 4 90 89.898 5 90 89.187 6 90 88.682 7 86 88.025 8 86 87.517 9 86 87.158 10 86 86.786 11 86 86.388 12 86 86.112 24 86 82.202 36 48 Kaplan-Meier Actuarial Survival % Survival J Heart Lung Transplant 2007;26: 769-7
Slide 18: HeartWare LVAD Flow: Enables Circadian Rhythm
HeartWare LVAD Flow: Enables Circadian Rhythm Day Night Caution - Investigational Device, Limited by United States Law to Investigational Use
Slide 19: LVAD Market Dynamics Very Favorable
LVAD Market Dynamics Very Favorable Patient population continues to grow VAD's are suddenly an attractive sector Market growth has exceeded almost all expectations Thoratec up 44% Q2 over Q2 '07 26 new centers started implanting in Q2 in US Cardiology meetings which were previously neutral to negati
Slide 20: Operational Update
Operational Update Capacity expansion and capability requirements identified during 2007 Requirement #1 - General facility upgrade Requirement #2 - Expanded clean room capability Requirement #3 - Validation / verification of all equipment and processes Requirement #4 - Yield and throughput improveme
Slide 21: Clean Room Upgrade
"Telephone Box" Clean Room ISO Class 100,000 Clean Rom Miami Lakes Significant Upgrade Clean Room Then: 180 sq ft Clean Room Now: 4,700 sq ft Caution - Investigational Device, Limited by United States Law to Investigational Use
Slide 22: Validation / verification of equipment and processes
Validation / verification of equipment and processes Relocation to "state-of-the-art" clean room in Miami Lakes Quality system upgrade Received ISO 13485 Certification Expanded capacity/reduced cycle time in receiving and inspection Partnered closely with key suppliers Ramped up in-house inventory d
Slide 23: MVAD's Promise
MVAD's Promise Growing 3 distinct surgical implantation approaches have emerged Trans apical (pictured) Less invasive full flow (7 liters+) Less invasive partial flow (3-4 liters) Physician feedback / interest very high "WOW" is most common comment Received high praise at ISRBP Configurability / ver
Slide 24: Transcutaneous Energy Transfer showing significant progress
Transcutaneous Energy Transfer showing significant progress Designed to enable transfer of energy and information across the skin Replaces driveline cable and eliminates risk of driveline complications Designed to enable patient to be un- tethered from the charging system for extended periods Pre-cl
Slide 25: Milestone Review
Milestone Review Milestone Timing Status Receipt of full IDE from FDA Q3 2008 Commencement of US Clinical Trial Q3 2008 Raise Capital Q3 2008 First Revenue Q3 2008 Submission of Technical Dossier Q3 2008 Upgrade Operations Facility Q3 2008 ISO Certification Q4 2008 Receipt of CE Mark Q4 2008 On Targ
Slide 26: Thank You
Thank You 25
Slide 27: Share Scheme Meeting
Share Scheme Meeting 'That pursuant to, and in accordance with section 411 of the Corporations Act 2001, the arrangement proposed between the Company and the holders of its fully paid ordinary shares (the Share Scheme), the terms of which are described in the Information Memorandum, is agreed to and
Slide 28: Option Scheme Meeting
Option Scheme Meeting 'That pursuant to, and in accordance with section 411 of the Corporations Act 2001, the arrangement proposed between the Company and the holders of options to acquire fully paid ordinary shares issued under the HeartWare Limited Employee Share Option Plan (Option Scheme), the t
Slide 29: Performance Rights Scheme Meeting
Performance Rights Scheme Meeting 'That pursuant to, and in accordance with section 411 of the Corporations Act 2001, the arrangement proposed between the Company and the holders of performance rights granted under the HeartWare Limited Performance Rights Plan ( Performance Rights Scheme), the terms
Slide 30: Extraordinary General Meeting of Shareholders
Extraordinary General Meeting of Shareholders 'That, for the purposes of section 162(m) and 422 of the US Internal Revenue Code (as amended) and for all other purposes, approval is given to the HeartWare International 2008 Stock Incentive Plan as described in section 8 and Appendix 11 of the Informa
Slide 31: Thank You
Thank You
Slide 32: Meetings of Shareholders and Incentive Holders: Chairman's Script
1 HEARTWARE LIMITED MEETINGS OF SHAREHOLDERS AND INCENTIVE HOLDERS PURSUANT TO THE INFORMATION MEMORANDUM DATED 12 SEPTEMBER 2008 CHAIRMAN’S SCRIPT